# Entrada Therapeutics, Inc.: financial statements, quarterly

TRDA · Nasdaq · CIK 1689375 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/trda.md) · [Financials](/companies/trda/financials.md) · [Filings](/companies/trda/filings.md) · [Insiders](/companies/trda/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/trda/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [43.7](/filings/0001689375-24-000063.md) | [41.8 d](/filings/0001689375-25-000011.md) | [59.1](/filings/0001689375-25-000024.md) | [94.7](/filings/0001689375-25-000043.md) | [19.6](/filings/0001689375-25-000050.md) | [37.4 d](/filings/0001689375-26-000011.md) | [20.6](/filings/0001689375-26-000028.md) | [2.0](/filings/0001689375-26-000054.md) | [1.6](/filings/0001689375-25-000050.md) | [1.3 d](/filings/0001689375-26-000011.md) | [0.9](/filings/0001689375-26-000028.md) | [0.9](/filings/0001689375-26-000054.md) |
| Research and development | $m | [22.2](/filings/0001689375-24-000063.md) | [28.3 d](/filings/0001689375-25-000011.md) | [28.6](/filings/0001689375-25-000024.md) | [32.0](/filings/0001689375-25-000043.md) | [31.3](/filings/0001689375-25-000050.md) | [33.4 d](/filings/0001689375-26-000011.md) | [32.1](/filings/0001689375-26-000028.md) | [37.9](/filings/0001689375-26-000054.md) | [38.4](/filings/0001689375-25-000050.md) | [34.0 d](/filings/0001689375-26-000011.md) | [33.1](/filings/0001689375-26-000028.md) | [35.4](/filings/0001689375-26-000054.md) |
| Operating income | $m | [14.0](/filings/0001689375-24-000063.md) | [4.9 d](/filings/0001689375-25-000011.md) | [21.1](/filings/0001689375-25-000024.md) | [53.4](/filings/0001689375-25-000043.md) | [(21.7)](/filings/0001689375-25-000050.md) | [(5.9) d](/filings/0001689375-26-000011.md) | [(21.8)](/filings/0001689375-26-000028.md) | [(46.8)](/filings/0001689375-26-000054.md) | [(47.1)](/filings/0001689375-25-000050.md) | [(42.2) d](/filings/0001689375-26-000011.md) | [(42.3)](/filings/0001689375-26-000028.md) | [(45.0)](/filings/0001689375-26-000054.md) |
| Income tax | $m | [(17.4)](/filings/0001689375-24-000063.md) | [18.7 d](/filings/0001689375-25-000011.md) | [1.8](/filings/0001689375-25-000024.md) | [2.8](/filings/0001689375-25-000043.md) | [(1.9)](/filings/0001689375-25-000050.md) | [(1.9) d](/filings/0001689375-26-000011.md) | [0.0](/filings/0001689375-26-000028.md) | [0.2](/filings/0001689375-26-000054.md) | [0.7](/filings/0001689375-25-000050.md) | [0.1 d](/filings/0001689375-26-000011.md) | [0.0](/filings/0001689375-26-000028.md) | [0.0](/filings/0001689375-26-000054.md) |
| Net income | $m | [35.5](/filings/0001689375-24-000063.md) | [(9.5) d](/filings/0001689375-25-000011.md) | [23.5](/filings/0001689375-25-000050.md) | [55.0](/filings/0001689375-25-000050.md) | [(14.0)](/filings/0001689375-25-000050.md) | [1.1 d](/filings/0001689375-26-000011.md) | [(17.3)](/filings/0001689375-26-000054.md) | [(43.1)](/filings/0001689375-26-000054.md) | [(44.1)](/filings/0001689375-25-000050.md) | [(39.2) d](/filings/0001689375-26-000011.md) | [(39.7)](/filings/0001689375-26-000054.md) | [(42.8)](/filings/0001689375-26-000054.md) |
| Diluted EPS | $ per share | [1.02](/filings/0001689375-24-000063.md) | not reported | [0.68](/filings/0001689375-25-000024.md) | [1.55](/filings/0001689375-25-000043.md) | [(0.35)](/filings/0001689375-25-000050.md) | not reported | [(0.42)](/filings/0001689375-26-000028.md) | [(1.04)](/filings/0001689375-26-000054.md) | [(1.06)](/filings/0001689375-25-000050.md) | not reported | [(0.95)](/filings/0001689375-26-000028.md) | [(1.01)](/filings/0001689375-26-000054.md) |
| Basic EPS | $ per share | [1.07](/filings/0001689375-24-000063.md) | not reported | [0.70](/filings/0001689375-25-000024.md) | [1.61](/filings/0001689375-25-000043.md) | [(0.35)](/filings/0001689375-25-000050.md) | not reported | [(0.42)](/filings/0001689375-26-000028.md) | [(1.04)](/filings/0001689375-26-000054.md) | [(1.06)](/filings/0001689375-25-000050.md) | not reported | [(0.95)](/filings/0001689375-26-000028.md) | [(1.01)](/filings/0001689375-26-000054.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [51.9](/filings/0001689375-23-000074.md) | [67.6](/filings/0001689375-25-000011.md) | [68.4](/filings/0001689375-24-000027.md) | [185](/filings/0001689375-24-000047.md) | [78.0](/filings/0001689375-24-000063.md) | [101](/filings/0001689375-26-000011.md) | [67.8](/filings/0001689375-25-000024.md) | [72.5](/filings/0001689375-25-000043.md) | [93.3](/filings/0001689375-25-000050.md) | [90.4](/filings/0001689375-26-000054.md) | [76.4](/filings/0001689375-26-000028.md) | [99.3](/filings/0001689375-26-000054.md) |
| Current assets | $m | [383](/filings/0001689375-23-000074.md) | [370](/filings/0001689375-25-000011.md) | [414](/filings/0001689375-24-000027.md) | [490](/filings/0001689375-24-000047.md) | [465](/filings/0001689375-24-000063.md) | [440](/filings/0001689375-26-000011.md) | [403](/filings/0001689375-25-000024.md) | [369](/filings/0001689375-25-000043.md) | [338](/filings/0001689375-25-000050.md) | [306](/filings/0001689375-26-000054.md) | [267](/filings/0001689375-26-000028.md) | [233](/filings/0001689375-26-000054.md) |
| Total assets | $m | [485](/filings/0001689375-23-000074.md) | [469](/filings/0001689375-25-000011.md) | [511](/filings/0001689375-24-000027.md) | [582](/filings/0001689375-24-000047.md) | [555](/filings/0001689375-24-000063.md) | [526](/filings/0001689375-26-000011.md) | [486](/filings/0001689375-25-000024.md) | [449](/filings/0001689375-25-000043.md) | [413](/filings/0001689375-25-000050.md) | [377](/filings/0001689375-26-000054.md) | [336](/filings/0001689375-26-000028.md) | [299](/filings/0001689375-26-000054.md) |
| Current liabilities | $m | [165](/filings/0001689375-23-000074.md) | [159](/filings/0001689375-25-000011.md) | [174](/filings/0001689375-24-000027.md) | [85.8](/filings/0001689375-24-000047.md) | [70.6](/filings/0001689375-24-000063.md) | [39.5](/filings/0001689375-26-000011.md) | [18.4](/filings/0001689375-25-000024.md) | [19.8](/filings/0001689375-25-000043.md) | [24.0](/filings/0001689375-25-000050.md) | [24.5](/filings/0001689375-26-000054.md) | [19.2](/filings/0001689375-26-000028.md) | [21.4](/filings/0001689375-26-000054.md) |
| Total liabilities | $m | [238](/filings/0001689375-23-000074.md) | [227](/filings/0001689375-25-000011.md) | [241](/filings/0001689375-24-000027.md) | [152](/filings/0001689375-24-000047.md) | [132](/filings/0001689375-24-000063.md) | [97.6](/filings/0001689375-26-000011.md) | [69.2](/filings/0001689375-25-000024.md) | [69.3](/filings/0001689375-25-000043.md) | [72.2](/filings/0001689375-25-000050.md) | [71.2](/filings/0001689375-26-000054.md) | [64.7](/filings/0001689375-26-000028.md) | [65.5](/filings/0001689375-26-000054.md) |
| Shareholders' equity | $m | [247](/filings/0001689375-24-000063.md) | [242](/filings/0001689375-26-000011.md) | [269](/filings/0001689375-25-000050.md) | [430](/filings/0001689375-25-000050.md) | [422](/filings/0001689375-25-000050.md) | [429](/filings/0001689375-26-000054.md) | [417](/filings/0001689375-26-000054.md) | [380](/filings/0001689375-26-000054.md) | [341](/filings/0001689375-25-000050.md) | [306](/filings/0001689375-26-000054.md) | [271](/filings/0001689375-26-000054.md) | [233](/filings/0001689375-26-000054.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(24.5) d](/filings/0001689375-24-000063.md) | [(4.0) d](/filings/0001689375-25-000011.md) | [(25.5)](/filings/0001689375-25-000024.md) | [39.8 d](/filings/0001689375-25-000043.md) | [(24.3) d](/filings/0001689375-25-000050.md) | [(31.6) d](/filings/0001689375-26-000011.md) | [(38.5)](/filings/0001689375-26-000028.md) | [(29.5) d](/filings/0001689375-26-000054.md) | [(28.3) d](/filings/0001689375-25-000050.md) | [(32.2) d](/filings/0001689375-26-000011.md) | [(41.7)](/filings/0001689375-26-000028.md) | [(32.5) d](/filings/0001689375-26-000054.md) |
| Capital expenditure | $m | [1.4 d](/filings/0001689375-24-000063.md) | [1.0 d](/filings/0001689375-25-000011.md) | [0.8](/filings/0001689375-25-000024.md) | [1.0 d](/filings/0001689375-25-000043.md) | [0.6 d](/filings/0001689375-25-000050.md) | [0.6 d](/filings/0001689375-26-000011.md) | [1.1](/filings/0001689375-26-000028.md) | [0.3 d](/filings/0001689375-26-000054.md) | [(0.2) d](/filings/0001689375-25-000050.md) | [(0.2) d](/filings/0001689375-26-000011.md) | [0.0](/filings/0001689375-26-000028.md) | [0.0 d](/filings/0001689375-26-000054.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [31.3](/filings/0001689375-23-000074.md) | [32.4](/filings/0001689375-24-000027.md) | [33.2](/filings/0001689375-24-000047.md) | [34.8](/filings/0001689375-24-000063.md) | [34.8](/filings/0001689375-25-000024.md) | [35.5](/filings/0001689375-25-000043.md) | [40.6](/filings/0001689375-25-000050.md) | [41.1](/filings/0001689375-26-000028.md) | [41.3](/filings/0001689375-26-000054.md) | [41.5](/filings/0001689375-25-000050.md) | [41.8](/filings/0001689375-26-000028.md) | [42.2](/filings/0001689375-26-000054.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 38,936,669 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001689375-26-000054.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.